Liposomal topotecan formulation with a low polyethylene glycol grafting density: Pharmacokinetics and antitumour activity

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 3, 2012, Pages 372-382

  Li, Chunlei ^a,c,d   Wang, Caixia ^a,c,d   Yang, Hanyu ^a,c,d   Zhao, Xi ^a,c,d   Wei, Na ^a,c,d   Cui, Jingxia ^b  

^a State Key Lab of Novel Pharmaceutical Preparations and Excipients   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^d CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

Author keywords

antineoplastic effect; dose schedule; liposomes; pharmacokinetics; topotecan

Indexed keywords

AMMONIUM SULFATE; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; MACROGOL; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; ENCAPSULATION; EXPERIMENTAL DOG; FEMALE; HUMAN; LEWIS CARCINOMA; LIPOSOMAL DELIVERY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; RAT; TISSUE DISTRIBUTION; TOXICITY TESTING;

AMMONIUM SULFATE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARCINOMA, LEWIS LUNG; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HAND-FOOT SYNDROME; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA L1210; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SKIN; SKIN DISEASES; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84857064441     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01422.x     Document Type: Article

References (26)

1. Papahadjopoulos D, et al,. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991; 88: 11460-11464. (Pubitemid 21916061)
2. Allen TM, et al,. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006; 6: 513-523. (Pubitemid 44697110)
3. Allen TM, Martin FJ,. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004; 31 (6 Suppl. 13): 5-15. (Pubitemid 40023239)
4. Gabizon A, et al,. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419-436. (Pubitemid 36649037)
5. Gabizon A, et al,. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998; 53: 275-279. (Pubitemid 28218710)
6. Fenske DB, Cullis PR,. Liposomal nanomedicines. Expert Opin Drug Deliv 2008; 5: 25-44. (Pubitemid 351234108)
7. Fenske DB, et al,. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008; 36: 21-29.
8. Zhu G, et al,. The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 1996; 39: 138-142. (Pubitemid 26400672)
9. Goren D, et al,. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Biochim Biophys Acta 1990; 1029: 285-294. (Pubitemid 20372065)
10. Vail DM, et al,. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50: 131-136. (Pubitemid 34969509)
11. Nicum SJ, O'Brien ME,. Topotecan for the treatment of small-cell lung cancer. Expert Rev Anticancer Ther 2007; 7: 795-801. (Pubitemid 47007986)
12. Garst J,. Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert Opin Drug Saf 2007; 6: 53-62. (Pubitemid 46138608)
13. Ackermann S, et al,. Topotecan in cervical cancer. Int J Gynecol Cancer 2007; 17: 1215-1223. (Pubitemid 350077343)
14. Abraham SA, et al,. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 2004; 96: 449-461. (Pubitemid 38553923)
15. Liu JJ, et al,. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 2002; 13: 709-717.
16. Tardi P, et al,. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000; 60: 3389-3393. (Pubitemid 30482152)
17. Haran G, et al,. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201-215. (Pubitemid 23283973)
18. Vail DM, et al,. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004; 31: (6 Suppl. 13): 16-35. (Pubitemid 40023240)
19. Working PK, Dayan AD,. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996; 15: 751-785. (Pubitemid 26331691)
20. Li C, et al,. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 2008; 70: 657-665.
21. Kenworthy AK, et al,. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 1995; 68: 1921-1936.
22. Needham D, et al,. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197-1201. (Pubitemid 30151982)
23. Gabizon A, et al,. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992. (Pubitemid 24085451)
24. Randall-Whitis LM, Monk BJ,. Topotecan in the management of cervical cancer. Expert Opin Pharmacother 2007; 8: 227-236. (Pubitemid 46206624)
25. O'Brien M, et al,. Recent advances with topotecan in the treatment of lung cancer. Oncologist 2007; 12: 1194-1204. (Pubitemid 350106350)
26. Gabizon A, et al,. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10: 539-548. (Pubitemid 36124352)